| Literature DB >> 28978171 |
Jianfeng Cui1, Meng Yu1, Ning Zhang1, Shiyu Wang1, Yaofeng Zhu1, Shouzhen Chen1, Kejia Zhu1, Jian Du1, Hongda Zhao1, Xigao Liu1, Pengxiang Chen2, Wenbo Wang3, Dongqing Zhang1, Benkang Shi1.
Abstract
This study is to clarify the prognostic value of preoperative plasma fibrinogen and serum albumin level, as known as FA score, in a cohort of Chinese patients with upper urinary tract urothelial carcinoma (UTUC). We retrospectively evaluated clinicopathological data on 169 patients who underwent surgery between 2006 and 2013. The FA score was calculated based on cutoff values of 3.53g/L for fibrinogen and 43.56 g/L for albumin. Overall survival and cancer specific survival was assessed using the Kaplan-Meier method and the equivalences of the curves were tested by log-rank tests. The Cox proportional hazards regression model was applied in univariate and multivariate analyses. In univariate analysis, tumor size, tumor grade, pathological T stage and FA score were significantly associated with overall survival and cancer specific survival, and multivariate Cox proportional hazards regression analysis identified FA score (score 1: HR=3.486, 95%CI 1.358-8.948, p=0.009; HR=3.485, 95%CI 1.363-8.913, p=0.009, respectively; score 2: HR=5.509, 95%CI 2.144-14.158, p<0.001; HR=5.521, 95%CI 2.074-14.697, p=0.001, respectively) was an independent predictor for overall survival and cancer specific survival. The evaluation of preoperative FA score can be regarded as an independent prognostic factor for predicting overall survival and cancer specific survival in UTUC. The fibrinogen and albumin levels are low cost and easy accessibility in clinical practice.Entities:
Keywords: plasma fibrinogen; prognosis; serum albumin; upper urinary tract urothelial carcinoma
Year: 2017 PMID: 28978171 PMCID: PMC5620311 DOI: 10.18632/oncotarget.16483
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Clinicopathologic characteristics and FA score of 169 patients with upper tract urothelial cancer (UTUC)
| All Patients (n=169) | FA score | P value | ||||
|---|---|---|---|---|---|---|
| 0 (n=36) | 1 (n=79) | 2 (n=54) | ||||
| Gender | Male/Female | 107 (63.3%)/62 (36.7%) | 19 (52.8%)/17 (47.2%) | 54 (68.4%)/25 (31.6%) | 34 (63.0%)/20 (37.0%) | 0.274 |
| Age, year | Mean±SD | 65.66±9.98 | 62.90±10.71 | 66.00±9.70 | 66.94±9.74 | 0.166 |
| Median (range) | 66 (36-87) | 63.5 (42-85) | 67 (40-84) | 68 (36-87) | ||
| History of Smoking | Yes | 38(22.5%) | 7 (19.4%) | 22 (27.8%) | 9 (16.7%) | 0.28 |
| no | 131(77.5%) | 29 (80.6%) | 57 (72.2%) | 45 (83.3%) | ||
| History of Bladder Cancer n(%) | Yes | 15 (8.9%) | 3 (8.3%) | 10 (12.7%) | 2 (3.7%) | 0.202 |
| No | 154 (91.1%) | 33 (91.7%) | 69 (87.3%) | 52 (96.3%) | ||
| Tumor Location n(%) | Renal pelvis | 66 (39.1%) | 18 (50.0%) | 33 (41.8%) | 15 (27.8%) | 0.066 |
| Ureter | 98 (58.0%) | 16 (44.4%) | 43 (54.4%) | 39 (72.2%) | ||
| Both | 5 (2.9%) | 2 (5.6%) | 3 (3.8%) | 0 (0%) | ||
| Tumor Focality n(%) | Unifocal | 159 (94.1%) | 34 (94.4%) | 74 (93.7%) | 51 (94.4%) | 0.978 |
| Multifocal | 10(5.9%) | 2 (5.6%) | 5 (6.3%) | 3 (5.6%) | ||
| Tumor Size n(%) | <4cm | 116 (68.6%) | 26 (72.2%) | 49 (62.0%) | 41 (75.9%) | 0.207 |
| ≥4cm | 53 (31.4%) | 10 (27.8%) | 30 (38.0%) | 13 (24.1%) | ||
| Tumor Grade n(%) | G1-2 | 46 (27.2%) | 13 (36.1%) | 16 (20.3%) | 17 (31.5%) | 0.145 |
| G3 | 123 (72.8%) | 23 (63.9%) | 63 (79.7%) | 37 (68.5%) | ||
| Pathological T Stage n(%) | pTa/T1 | 57 (33.7%) | 14 (38.9%) | 30 (38.0%) | 13 (24.1%) | 0.282 |
| pT2-4 | 112 (66.3%) | 22 (61.1%) | 49 (62.0%) | 41 (75.9%) | ||
| Lymph node metastasis n(%) | pNx/ pN0 | 158 (93.5%) | 36 (100%) | 77 (97.4%) | 45 (83.3%) | 0.001 |
| pN+ | 11 (6.5%) | 0 (0%) | 2 (2.6%) | 9 (16.7%) | ||
| Lymphovascular invasion | Negative | 137 (81.1%) | 31 (86.1%) | 66 (83.5%) | 40 (74.1%) | 0.268 |
| Positive | 32 (18.9%) | 5 (13.9%) | 13 (16.5%) | 14 (25.9%) | ||
| ECOG-PS n(%) | 0 | 159 (94.1%) | 35 (97.2%) | 74 (93.7%) | 50 (92.6%) | 0.645 |
| ≥1 | 10 (5.9%) | 1 (2.8%) | 5 (6.3%) | 4 (7.4%) | ||
| Operation approach n(%) | RNU | 147 (87.0%) | 34 (94.4%) | 69 (87.3%) | 44 (81.5%) | 0.2 |
| SR | 22 (13.0%) | 2 (5.6%) | 10 (12.7%) | 10 (18.5%) | ||
| Adjuvant Chemotherapy or Radiotherapy n(%) | Yes | 155 (91.7%) | 33 (91.7%) | 71 (89.9%) | 51 (94.4%) | 0.643 |
| No | 14 (8.3%) | 3 (8.3%) | 8 (10.1%) | 3 (5.6%) | ||
| Albumin (g/L) | Mean±SD | 41.84±4.15 | 46.22±2.04 | 41.23±4.18 | 39.80±2.86 | |
| Median (range) | 42.0 (27.3-52.7) | 45.8 (43.7-52.7) | 41.4 (27.3-50.7) | 40.0 (34.1-43.6) | ||
| Fibrinogen (g/L) | Mean±SD | 3.59±1.06 | 2.96±0.44 | 3.18±0.76 | 4.62±0.99 | |
| Median (range) | 3.39 (1.50-7.70) | 3.00 (2.14-3.92) | 3.03 (1.50-5.17) | 4.30(3.53-7.7) | ||
SD = Standard Deviation, pN+=pN1, pN2 or pN3, ECOG-PS = Eastern Cooperative Oncology Group performance status, RNU = Radical nephroureterectomy, SR = Segmental resection
Figure 1ROC analysis of optimal fibrinogen, albumin and FA score cutoff
Univariate Cox proportional hazard regression analyses of overall survival (OS) and cancer-specific survival (CSS) in 169 patients with UTUC
| Variable | OS | CSS | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Gender | ||||
| Male | 1.000 (reference) | 0.26 | 1.000 (reference) | 0.400 |
| Female | 0.749 (0.453-1.239) | 0.799 (0.473-1.349) | ||
| Age (years) | ||||
| <65 | 1.000 (reference) | 0.199 | 1.000 (reference) | 0.091 |
| ≥65 | 1.369 (0.847-2.221) | 1.564 (0.931-2.626) | ||
| History of Smoking | ||||
| No | 1.000 (reference) | 0.521 | 1.000 (reference) | 0.763 |
| Yes | 1.196 (0.692-2.069) | 1.096 (0.604-1.989) | ||
| Tumor Size | ||||
| <4cm | 1.00 (reference) | 0.036 | 1.000 (reference) | 0.048 |
| ≥4cm | 1.666 (1.033-2.685) | 1.677 (1.004-2.765) | ||
| Tumor Grade | ||||
| G1-2 | 1.000 (reference) | 0.009 | 1.000 (reference) | 0.009 |
| G3 | 2.290 (1.230-4.263) | 2.450 (1.246-4.820) | ||
| Tumor Stage | ||||
| pTa/T1 | 1.00 (reference) | <0.001 | 1.000 (reference) | <0.001 |
| pT2-4 | 3.807 (2.137-6.784) | 4.795 (2.479-9.274) | ||
| LVI | ||||
| Negative | 1.00 (reference) | 0.226 | 1.00 (reference) | 0.223 |
| Positive | 1.391(0.815-2.376) | 1.435(0.803-2.564) | ||
| FA score | ||||
| 0 | 1.000 (reference) | 1.000 (reference) | ||
| 1 | 3.537 (1.380-9.064) | 0.009 | 3.296 (1.290-8.419) | 0.013 |
| 2 | 5.687 (2.219-14.574) | <0.001 | 4.104 (1.559-10.804) | 0.004 |
OS = overall survival, CSS = cancer-specific survival, HR = hazard ratio, CI = confidence interval, LVI = Lymphovascular invasion, FA score = fibrinogen and albumin score
Multivariate Cox proportional hazard regression analyses of overall survival (OS) and cancer-specific survival (CSS) in 169 patients with UTUC
| Variable | OS | CSS | ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Tumor Size | ||||
| <4cm | 1.000 (reference) | 0.011 | 1.000 (reference) | 0.008 |
| ≥4cm | 1.865 (1.154-3.016) | 2.014 (1.196-3.391) | ||
| Tumor Grade | ||||
| G1-2 | 1.000 (reference) | 0.077 | 1.000 (reference) | 0.061 |
| G3 | 1.779 (0.940-3.368) | 1.924 (0.970-3.816) | ||
| Tumor Stage | ||||
| pTa/T1 | 1.000 (reference) | <0.001 | 1.000 (reference) | <0.001 |
| pT2-4 | 3.359 (1.860-6.066) | 5.030 (2.577-9.819) | ||
| FA score | ||||
| 0 | 1.000 (reference) | 1.000 (reference) | ||
| 1 | 3.486 (1.358-8.948) | 0.009 | 3.485 (1.363-8.913) | 0.009 |
| 2 | 5.509 (2.144-14.158) | <0.001 | 5.521 (2.074-14.697) | 0.001 |
OS = overall survival, CSS = cancer-specific survival, HR = hazard ratio, CI = confidence interval, FA score = fibrinogen and albumin score
Figure 2Kaplan-Meier survival curves of all patients with upper urinary tract urothelial carcinoma stratified by FA score, a. overall survival (OS); b. cancer specific survival
Figure 3Kaplan-Meier survival curves for 3-year and 5-year overall survival (OS) of 161 and 92 patients with upper urinary tract urothelial carcinoma stratified by FA score, respectively, a. 3-OS; b. 5-OS
Figure 4Kaplan-Meier survival curves of Ta/T1 patients with upper urinary tract urothelial carcinoma stratified by FA score, a. overall survival (OS); b. cancer specific survival
Figure 5Kaplan-Meier survival curves of T2-4 patients with upper urinary tract urothelial carcinoma stratified by FA score, a. overall survival (OS); b. cancer specific survival